Comparative effect of vildagliptin and teneligliptin on HbA1c, glycemic efficacy and insulin sensitivity


  • Tushar B. Chudiwal Department of Pharmacology, Ananta Institute of Medical Science and Research Centre, Rajsamand, Rajasthan, India



Glycemic efficacy, HbA1c, Homeostasis model assessment-R, Insulin sensitivity, Teneligliptin, Vildagliptin


Background: Vildagliptin, a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor, increases the availability of endogenous incretin hormones, glucagon-like peptide (GLP-1), and glucose-dependent insulinotropic polypeptide, thereby improving glycemic control. The objective of this study is to further investigate the insulin sensitizing properties of Vildagliptin in comparison to those of Teneligliptin.

Methods: Naive subjects with T2DM were administered 50-100mg/day Vildagliptin monotherapy (n = 53). As a comparator, monotherapy, 20mg/day Teneligliptin monotherapy was performed in a non-randomized manner (n=58). No other drugs were administered. At 3 month, levels of diabetic parameters were compared with those at baseline.

Results: At 3 months, while similar reductions of glycated hemoglobin (HbA1c) levels were observed with these two drugs, indexes for insulin sensitivity homeostasis model assessment (HOMA)-R ameliorated only with Vildagliptin. Then, the subjects were divided into two groups representing distinct degrees of insulin resistance; high HOMA-R (C4) and low HOMA-R (2) groups. With Vildagliptin, similar decreases of HbA1c levels were observed in high (10.85-8.66%, p\0.0005) and low (11.12-8.91%, p\0.01) HOMA-R groups. HOMA-R (-31.9%, p\0.05) and non-high density lipoprotein cholesterol (non-HDL-C, -7%, p\0.05) levels significantly decreased. HOMA-B levels increased in both groups with significant inter-group differences (102.1 % in low HOMA-R group vs. 53.4 % in high HOMA-R group). Group 2. With Teneligliptin similar decreases of HbA1c levels were observed from those of vildagliptin in either high or low HOMA-R group, but no changes of HOMA-R, non-HDL-C levels were noted. Increases of HOMA-B levels with teneligliptin were comparable to those with vildagliptin in either high or low HOMA-R group.

Conclusions: These results indicate that vildagliptin ameliorates insulin sensitivity and non-HDL-C levels in subjects with high degrees of insulin resistance and vildagliptin also shows glycemic efficacy by decreasing HbA1c. This is not the case with teneligliptin though similar glycemic efficacies were observed.


Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, et al. The dipeptidyl Peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose. Administration in type 2 diabetic patients. J Clin Endocrinol Metab. 2007;92:1249-55.

Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, et al. Vildagliptin, a dipeptidyl peptidase 4 inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab. 2005;90:4888-94.

Harada N, lnagaki N. Incretin and incretin-based therapies. Nihon Rinsho. 2010;68(5):931-42.

Nakamaru Y, Hayashi Y, Ikegawa R, Kinoshita S, Madera BP, Gunput D, et al. Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans. Xenobiotica. 2014;44(3):242-53.

Kadowaki T, Kondo K. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2013;15(9):810-8.

Nakagami H, Pang Z, Shimosato T, Moritani T, Kurinami H, Koriyama H, et al. The dipeptidyl peptidase-4 inhibitor teneligliptin improved endothelial dysfunction and insulin resistance in the SHR/NDmcr-cp rat model of metabolic syndrome. Hypertens Res. 2014;37(7):629-35.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Tumer RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-9.

Ohkura T, Shiochi H, Fujioka Y, Sumi K, Yamamoto N, Matsuzawa K, et al. 20/ (fasting C-peptide 9 fasting plasma glucose) is a simple and effective index of insulin resistance in patients with type 2 diabetes mellitus: a preliminary report. Cardiovasc Diabetol. 2013;12:21.

Kutoh E, Hirate M, Wada A. Distinct glucose-lowering properties in good responders treated with sitagliptin and alogliptin. Int J Clin Pract. 2015;69(11):1296-302.

Hong AR, Leeb J, Kuwangbob EJ, Kyoung MK. Comparison of Vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea. Diabetes Research and Clinical Practice. July 2015;109(1):141-8.

Bosi E. Vildagliptin Plus Metformin Combination therapy provides superior glycemic control to individual monotherapy in treatment-naive patients with type 2 Diabetes Mellitus. Diabetes Obes Metab. 2009;11:506-15.

Chun-Jun L, Xiao-Juan L, Bai L. Efficacy and Safety Of Vildagliptin, Saxagliptin Or Sitagliptin as an add-on Therapy in Chinese Patients with type 2 Diabetes, inadequately controlled with a dual combination of traditional oral hypoglycemic agents. Diabetology and Metabolic Syndrome. 2014;6(1).

American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2014;37(1):S14-80.

Ma Y, Olendzki BC, Merriam PA, Chiriboga DE, Culver AL, Li W, et al. A randomized clinical trial comparing low-glycemic index versus ADA dietary education among individuals with type 2 diabetes. Nutrition. 2008;24(1):45-56.

Miedema K. Towards worldwide standardisation of HbA1c determination. Diabetologia. 2004;47(7):1143-8.

Kutoh E, Fukushima T. Insulin-dependent actions of pioglitazone in newly diagnosed, drug naive patients with type 2 diabetes. Endocrine. 2009;35(3):333-40.

Tsuchimochi W, Ueno H, Yamashita E, Tsubouchi C, Sakoda H, Nakamura S, et al. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients. Endocr J. 2015;62(1):13-20.

Kishimoto M. Teneligliptin: A DPP-4 inhibitor for the treatment of type 2 diabetes. Diabetes Metab Syndr Obes. 2013;6:187-95.

Kadowaki T, Kondo K. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebocontrolled study with an open-label, long-term extension. Diabetes Obes Metab. 2014;16;418-25.

Kadowaki T, Kondo K. Efficacy and sagety of teneligliptin in combination with pioglitazone in Japanese Patients with type 2 diabetes mellitus. J Diabetes Investig. 2013;4;576-84.

Funahashi T, Matsuzawa Y. Obesity and diabetes mellitus. Nihon Naika Gakkai Z Asshi. 1996;85(4):578-82.

Liu A, Reaven GM. Is measurement of non-HDL cholesterol an effective way to identify the metabolic syndrome? Nutr Metab Cardiovasc Dis. 2013;23(11)1122-7.




How to Cite

Chudiwal, T. B. (2017). Comparative effect of vildagliptin and teneligliptin on HbA1c, glycemic efficacy and insulin sensitivity. International Journal of Basic & Clinical Pharmacology, 6(7), 1682–1688.



Original Research Articles